Abstract
Objective. Immunophilin FKBP51 assists polypeptide folding, participates in glucocorticoid actions and may play a role in glucocorticoid resistance. FKBP51 is altered in patients with asthma, but its role in chronic obstructive pulmonary disease (COPD) characterized by dysregulation of several pro/antiinflammatory genes is less clear. Methods. We assessed changes in nuclear/cytosolic FKBP51 protein using SDS-PAGE/WB and FKBP51 mRNA by qRT-PCR in cells isolated from induced sputum of stable COPD patients treated with formoterol/budesonide or formoterol/budesonide/theophylline for 4 wk. Results: Expression of FKBP51 was higher in formoterol/budesonide/theophylline-treated patients, compared with formoterol/budesonide group in both cytosolic and nuclear fractions by about 57% and 31%, respectively (P < 0.001, P < 0.01). FKBP51 mRNA was only slightly, but not significantly, higher in patients on formoterol/budesonide/theophylline. Conclusions: Increased FKBP51 in COPD patients treated with formoterol/budesonide/theophylline may be important in altering signaling from corticosteroid receptors. © 2009 I. Holzapfel Publishers.
Author supplied keywords
Cite
CITATION STYLE
Holownia, A., Mroz, R. M., Kolodziejczyk, A., Chyczewska, E., & Braszko, J. J. (2009). Increased FKBP51 in induced sputum cells of chronic obstructive pulmonary disease patients after therapy. European Journal of Medical Research, 14(SUPPL.4), 108–111. https://doi.org/10.1186/2047-783X-14-S4-108
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.